Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures

Affiliations

¹ Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France.
² Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, France.
³ Department of Dermatology, Hôpital d'Instruction des Armées Begin, Saint Mandé, France.
⁴ Department of Dermatology, CHU Amiens-Picardie, Amiens, France.
⁵ Department of Dermatology, CHU Saint Etienne, Saint Etienne, France.
⁶ Department of Dermatology, Centre Hospitalier René Dubos, Pontoise, France.
⁷ Department of Dermatology, Centre Hospitalier Bretagne Sud, Lorient, France.
⁸ Department of Dermatology, Centre Hospitalier Le Havre, Le Havre, France.
⁹ Cabinet Médical, Paris, France.
¹⁰ Centre de Dermatologie Stanislas, Clinique Pasteur, Nancy, France.
¹¹ Department of Dermatology, Hopital Saint Joseph, Marseille, France.
¹² Department of Dermatology, Hôpital Paris Saint Joseph, Paris, France.
¹³ Department of Dermatology, Centre Hospitalier Régional Metz-Thionville, Thionville, France.
¹⁴ Centre de Santé Sabouraud, Hôpital Saint-Louis, Paris, France.
¹⁵ Cabinet Médical, Saint-Maur-des-Fossés, France.
¹⁶ Department of Dermatology, Centre Hospitalier Emile Roux, Le Puy-en-Velay, France.
¹⁷ Department of Dermatology, Centre Hospitalier d'Orléans, Orléans, France.
¹⁸ Cabinet Médical, Beauvais, France.
¹⁹ Department of Dermatology, CHI Poissy Saint Germain, Saint-Germain-en-Laye, France.

Z Reguiai et al. J Eur Acad Dermatol Venereol. 2023 Nov.

. 2023 Nov;37(11):e1307-e1309.

doi: 10.1111/jdv.19302. Epub 2023 Jul 14.

¹ Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France.
² Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, France.
³ Department of Dermatology, Hôpital d'Instruction des Armées Begin, Saint Mandé, France.
⁴ Department of Dermatology, CHU Amiens-Picardie, Amiens, France.
⁵ Department of Dermatology, CHU Saint Etienne, Saint Etienne, France.
⁶ Department of Dermatology, Centre Hospitalier René Dubos, Pontoise, France.
⁷ Department of Dermatology, Centre Hospitalier Bretagne Sud, Lorient, France.
⁸ Department of Dermatology, Centre Hospitalier Le Havre, Le Havre, France.
⁹ Cabinet Médical, Paris, France.
¹⁰ Centre de Dermatologie Stanislas, Clinique Pasteur, Nancy, France.
¹¹ Department of Dermatology, Hopital Saint Joseph, Marseille, France.
¹² Department of Dermatology, Hôpital Paris Saint Joseph, Paris, France.
¹³ Department of Dermatology, Centre Hospitalier Régional Metz-Thionville, Thionville, France.
¹⁴ Centre de Santé Sabouraud, Hôpital Saint-Louis, Paris, France.
¹⁵ Cabinet Médical, Saint-Maur-des-Fossés, France.
¹⁶ Department of Dermatology, Centre Hospitalier Emile Roux, Le Puy-en-Velay, France.
¹⁷ Department of Dermatology, Centre Hospitalier d'Orléans, Orléans, France.
¹⁸ Cabinet Médical, Beauvais, France.
¹⁹ Department of Dermatology, CHI Poissy Saint Germain, Saint-Germain-en-Laye, France.

No abstract available

References

1. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316-326.
1. Salinas CA, Louder A, Polinski J, Zhang TC, Bower H, Phillips S, et al. Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther. 2023;10:201-223.
1. Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9:e002735.
1. Bieber T, Katoh N, Simpson EL, de Bruin-Weller M, Thaçi D, Torrelo A, et al. Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials. J Dermatolog Treat. 2023;34:2161812.
1. Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther. 2022;35:e15636.